Neurizon completes Regimen I enrolment, accelerates NUZ-001 topline results to Q2 CY2027
Late-stage biotechnology company Neurizon Therapeutics (ASX: NUZ) has completed enrolment in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating its lead investigational therapy NUZ-001 for amyotrophic lateral sclerosis (ALS). The final participant has completed their baseline visit and commenced treatment.
With recruitment now complete, anticipated topline efficacy and safety results are expected in late Q2 CY2027, earlier than previously anticipated. The Company noted that completion of recruitment materially de-risks execution of its lead late-stage clinical program, bringing forward a key value inflection point.
A total of 250 participants were enrolled in less than five months from first participant dosing. This was achieved even after the planned sample size expansion from 160 to 240 participants, made in response to strong recruitment momentum.
The sample size expansion from 160 to 240 participants was announced in May 2026 with no change to funding requirements, supported by focused cost management, a philanthropic contribution from the Sean M. Healey and AMG Center, and the Australian Federal Government R&D Tax Incentive cash rebate.
When big ASX news breaks, our subscribers know first
A record pace across the HEALEY ALS Platform Trial network
Regimen I became the fastest regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial so far. Notably, this pace was maintained despite the planned increase in sample size.
Neurizon attributed the speed of enrolment to a combination of factors across the trial network, which spans clinical sites throughout the United States.
-
Strong recruitment momentum across the trial network
-
Operational efficiencies introduced under the trial’s next-generation master protocol
-
The commitment of investigators, research coordinators and clinical site teams across the United States
The Company acknowledged every person living with ALS and their families who chose to participate in the research, recognising their role as fundamental to advancing potential new treatment options.
| Milestone | Detail | Investor Impact |
|---|---|---|
| Enrolment completed | 250 participants in less than five months | Materially de-risks execution |
| Topline readout | Accelerated to late Q2 CY2027 | Brings forward value inflection |
| Sample size | Expanded 160 to 240 (planned) | Reflects recruitment strength |
What the HEALEY ALS Platform Trial means for NUZ-001
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial. It is conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States, created in partnership with the Network of Excellence for ALS (NEALS).
Entry into the trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS.
ALS is the most common form of motor neurone disease, a progressive neurodegenerative condition. This context underscores why the speed of clinical development carries particular significance for the patient community.
TDP-43 aggregation is the core driver of motor neuron degeneration present in approximately 97% of ALS cases, and NUZ-001’s mechanism targets this pathological hallmark directly, distinguishing it from approved therapies that address downstream symptoms and extend survival by only 2-6 months.
Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey & AMG Center and Executive Director of the Mass General Brigham Neuroscience Institute
“We are grateful to everyone who helped complete enrolment in Regimen I in such a short amount of time. We believe strongly in importance of speed, efficiency and high quality in clinical trials. Our patients tell us that the ALS clock is faster and we need to work collaboratively to develop treatments sooner. This is one of the guiding principles of the Healey ALS Platform Trial, Next Generation. The rapid speed of enrolment in this regimen is a testament to the hard work of participants and their families and study staff across all the participating NEALS sites, as well as to the optimised Platform Trial infrastructure.”
Next steps and the road to topline results
With enrolment complete, participants now progress through the defined phases of the trial. The Company’s focus centres on continued execution ahead of the anticipated topline readout.
-
Enrolment completed, final participant dosed (July 2026)
-
36-week Randomised Controlled Trial phase (underway)
-
36-week Active Treatment Extension phase (following)
-
Anticipated topline efficacy and safety results, late Q2 CY2027
The accelerated topline readout represents the key upcoming catalyst for shareholders, positioning the data event as a potential value inflection point for the Company.
Sergio Duchini, Interim Executive Chairman
“Completion of enrolment represents a major milestone in the clinical development of NUZ-001. Importantly, the rapid completion of recruitment has enabled the anticipated timing of topline efficacy and safety results to be accelerated into late Q2 CY2027, bringing forward an important value inflection point for Neurizon and our shareholders.
On behalf of the Company, I would like to sincerely thank every person living with ALS and their families who chose to participate in this trial. Their willingness to contribute to research despite the immense challenges of this disease is inspiring and is fundamental to advancing the development of new treatment options for people living with ALS.
I would also like to acknowledge the outstanding work of the HEALEY ALS Platform Trial team, investigators, research coordinators and clinical site teams whose expertise, collaboration and commitment have made this achievement possible.
With recruitment now complete, our focus turns to delivering the study with the same operational discipline that has characterised the program to date. We look forward to advancing NUZ-001 through clinical development and towards the anticipated topline efficacy and safety results.”
The next major ASX story will hit our subscribers first
Why this milestone matters for investors
The completion of enrolment materially de-risks execution of Neurizon’s lead late-stage asset. By bringing forward the anticipated topline readout, the accelerated timeline pulls forward the catalyst that could re-rate the Company.
It is important to note that NUZ-001 remains an investigational product and is not approved for commercial use in any jurisdiction. Trial results are pending, and no efficacy has yet been demonstrated.
With Regimen I fully enrolled, NUZ-001 is advancing toward a defined data readout within one of the world’s leading ALS clinical trial initiatives, keeping the late Q2 CY2027 milestone firmly in focus for shareholders.
Don’t Miss the Next ASX Healthcare Breakthrough
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive the moment market-moving healthcare announcements hit the ASX.